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Case Report
Acute Methotrexate Neurotoxicity with
Choreiform Movements and Focal Neurological
Deficits: A Case Report
Daniela A. Bota, MD, PhD, and Rima M. Dafer, MD
Abstract: Methotrexate (MTX) is an effective antimetabolite treat-
ment for various oncological disorders including the central nervous
system involvement (CNS) in widespread leukemia and CNS lym-
phoma. This form of treatment has a notable toxic effect on the
nervous system, and the pediatric population seems to be more
vulnerable to the neurologic toxicity of this drug. Though chronic
leukoencephalopathy from an MTX regimen, especially when ad-
ministered in conjunction with whole brain radiation, is well de-
scribed, the acute manifestations are rare and not well understood.
The diagnosis of acute focal symptoms from MTX treatment is
especially difficult in patients who receive chemotherapy for neo-
plastic disorders and who may have many reasons for CNS involve-
ment in general and parenchymal involvement in particular. We
report the unusual clinical and neuro-imaging findings in a teenager
with acute focal symptoms after MTX treatment for acute lympho-
blastic leukemia.
Key Words: acute lymphoblastic leukemia, methotrexate, neuro-
logic complications
Acute lymphoblastic leukemia (ALL) is the most commonform of childhood leukemia and one of the main causes
of cancer-related mortality in children.1 Improved outcomes
have been reached recently by the use of methotrexate (MTX)
therapy for the consolidation and prevention of relapse at
sanctuary sites such as the central nervous system (CNS).
However, this treatment is not without risks, the most severe
being neurotoxicity.2,3 In the acute phase, the patients present
with confusion,4 seizures,5 and focal neurologic deficits,6
which are sometimes followed by cognitive and developmen-
tal impairments secondary to persistent white matter lesions
in the chronic state.7,8
We describe the case of an adolescent patient with ALL
and neurotoxicity following intrathecal methotrexate and re-
view the current published literature.
Case Report
A 17-year-old male was diagnosed with ALL after
presenting with a 3-week history of fever, fatigue, de-
creased appetite, and weight loss. Immunophenotypic
analysis of the bone marrow showed a majority of im-
mature B-cells, which were diagnostic of precursor B-
cell acute lymphoblastic leukemia. The cerebrospinal
fluid (CSF) was negative for neoplastic cells. The patient
received a 6-week induction therapy with oral prednisone,
vincristine, daunomycin, and asparaginase and 4 doses of
intrathecal MTX. The last dose of asparaginase and
daunomycin were held after he developed pancreatitis.
He then received consolidation therapy with intrathecal
MTX, cytosine arabinoside, and oral 6-mercaptopurine.
Eight weeks into the beginning of treatment and af-
ter 5 doses of intrathecal MTX, he presented with con-
fusion, nausea, headache, unilateral choreiform move-
ments, and right side weakness. Examination revealed
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Key Points
• Acute lymphoblastic leukemia (ALL) is the most com-
mon form of childhood leukemia and one of the main
causes of cancer-related mortality in children.
• Methotrexate (MTX) is a folate antagonist widely used
in the treatment of ALL. It inhibits methionine syn-
thesis, an important metabolite necessary for central
nervous system myelination.
• Acute MTX neurotoxicity may have a wide spectrum
of clinical presentations and should be included in the
differential diagnosis of acute neurologic symptoms
for all patients treated with this drug.
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altered mental status, right facial droop, right arm and
leg weakness, right side ataxia out of proportion to the
weakness, ankle areflexia, and bilateral plantar extensor
responses. Diffusion-weighted magnetic resonance im-
aging (DW-MRI) showed areas of high signal intensity
within the centrum semi-ovale bilaterally (Fig. 1, C)
with normal T2 sequential imaging, fluid-attenuated in-
version-recovery (FLAIR), and T1 post-contrast imag-
ing (Figs. 1, A, B, and D). CSF analysis showed normal
protein and cellularity, no blasts, and negative cultures.
CNS levels of MTXwere not measured. Electroencepha-
lography (EEG) was normal. And, a spectroscopy study
was suggested but not performed.
The patient received dexamethasone with rapid clin-
ical improvement. On his tenth hospitalization day, he
received leucovorin 11 mg pre- and post-treatment with
intrathecal MTX. He tolerated his chemotherapy well
without recurrence of any neurologic symptoms. He was
discharged home 2 weeks later.
Neurological examination 2 months later revealed nor-
mal cognitive functions, a subtle right hemiparesis with
disappearance of ataxia and chorea. Follow-up brain MRI
showed chronic white matter changes with abnormal T2 and
FLAIR imaging (Figs. 2, A and B) suggestive of residual
gliosis and resolution of the diffusion abnormalities with
no contrast enhancement (Figs. 2, C and D).
Discussion
Cytotoxic agents such as methotrexate, carmustine, cis-
platin, cytarabine, fluorouracil, levamisole, fludarabine, thio-
tepa, interleukin-2, and interferon alfa9,10 are potent neuro-
toxins reported to cause widespread cortical, subcortical,
hippocampal, and white matter pathologies.11
MTX is a folate antagonist widely used in the treatment
of ALL. It inhibits methionine synthesis, an important me-
tabolite necessary for CNS myelination.12,13 Neurotoxicity
has been reported after acute, subacute, or chronic treatment
with MTX. Acute MTX neurotoxicity ranges from 3–10%
and varies with the dose and route of administration.3 The
time from induction to the onset of acute neurotoxicity varies
from 2–127 weeks and is more often seen 10–11 days after
intrathecal MTX induction therapy.
Neurological symptoms associated with MTX include
headaches, nausea, emesis, lethargy, mental status change,
cognitive impairments, Klu¨ver-Bucy syndrome, blurred vi-
sion, aphasia, transient or persistent hemiparesis, seizures,
choreiform movements, arachnoiditis, encephalomyelitis, and
death.2,5,14–16 Leukoencephalopathy has been observed in less
than 10% of patients after intravenous MTX administration
and up to 40% following intrathecal infusion.2,3,16,17
The mechanism for MTX-induced neurotoxicity re-
mains unclear. Various multifactorial mechanisms have
been suggested for the effects of MTX such as: the direct
toxic effect on myelin, inhibition of glucose metabo-
lism,18,19 injury to oligodendrocytes with disruption of my-
elin synthesis, disruption of mitochondrial energy metabo-
lism resulting in oxidative stress and increased vulnerability
of neurons to physiological glutamate concentrations,11 break-
down of the blood–brain barrier,17 and inhibition of the en-
zyme dihydrofolate reductase, which prevents the conversion
of folic acid to tetrahydrofolic acid and thereby increases the
levels of homocysteine and excitotoxic neurotransmitters and
inhibits cell replication.18,19
MTX neurotoxicity should be suspected in all patients
with acute neurologic findings receiving treatment for onco-
logical conditions. In this population, CSF analysis is usually
unremarkable. Electroencephalographic findings are usually
non-specific. Acutely, DW-MRI studies show white matter
changes probably due to demyelination.6,20,21 Magnetic res-
onance spectroscopy may demonstrate metabolite changes in
the absence of structural white matter abnormalities.22
The treatment of acute MTX toxicity is still open for
debate.
MTX neurotoxicity was reported to be reversible with
administration of dexamethasone and leucovorin.7,23 Leuco-
Fig. 1 Brain magnetic resonance imaging (MRI) at the initial
presentation with methotrexate (MTX) toxicity. (A) T2 sequence
imaging, (B) fluid-attenuated inversion-recovery (FLAIR), (C)
diffusion weighted (DW), (D) T1 postcontrast. Hyperdense le-
sions are noted bilaterally on DW in the centrum semiovale.
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vorin could antagonize the effects of MTX on purine me-
tabolism through maintenance of DNA/RNA synthesis, de-
spite the blockade of dihydrofolate reductase. Significant
improvement of neurological symptoms has also been achieved
with combined administration of aminophylline—an aden-
osine antagonist—and high dose folinic acid.24 Whether
glutamate antagonists could prevent neurotoxicity of MTX
when given with cancer chemotherapy remains to be
determined.25
Conclusion
Neurological complications of MTX are increasingly rec-
ognized with the advances of neuroimaging. Acute MTX neu-
rotoxicity may have a wide spectrum of clinical presentations
and should be included in the differential diagnosis of acute
neurologic symptoms for all the patients treated with this
drug. These symptoms and the MRI findings are usually re-
versible.
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Sail On, Sail On
Sail on, sail on, thou fearless bark–
Wherever blows the welcome wind,
It cannot lead to scenes more dark,
More sad than those we leave behind.
Each wave that passes seems to say,
“Tho’ death beneath our smile may be,
Less cold we are, less false than they,
Whose smiling wrecked thy hopes and thee.”
Sail on, sail on,–thro’ endless space–
Thro’ calm–thro’ tempest–stop no more:
The stormiest sea’s a resting place
To him who leaves such hearts on shore.
Or–if some desert land we meet,
Where never yet false-hearted men
Profaned a world, that else were sweet,–
Then rest thee, bark, but not till then.
—Thomas Moore
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